TORONTO, ONTARIO, November 14, 2025 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) (“COSCIENS” or the “Company”), a life sciences company specializing in natural ingredients and pharmaceutical solutions, today announced that Peter H. Puccetti, CFA, is Chairman of the Company’s Board of Directors (the “Company”)Board“), has been appointed interim CEO, effective immediately. Peter will succeed Anna Bean, who has stepped down as CEO.
“As the Company continues its efforts to reduce costs and streamline its organizational structure while aligning resources with key strategic priorities, the Board of Directors has determined that now is the right time for a leadership transition,” said Robert Seeger, Chairman of the Nominating, Nominating and Governance Committee. “Peter is already actively involved in the company's strategic turnaround and has a proven track record of creating value for similarly situated businesses. We are confident that Peter's leadership will serve the company well at this critical time.”
Mr. Puccetti said, “In my expanded role as Chairman and Interim CEO, I plan to continue to improve operating performance while working to create the conditions necessary to enhance shareholder value.” Mr. Puccetti continued: “On behalf of everyone at COSCIENS, I want to thank Anna for her professionalism, leadership and contributions. We wish her all the best in her future endeavors.”
About COSCIENS Biopharma Inc.
COSCIENS is a diversified life sciences company specializing in the development of natural active ingredients of plant origin and commercializing pharmaceutical and diagnostic products. COSCIENS' Natural Active Ingredients business uses the company's proprietary production and extraction technologies to develop the active ingredients avenanthramides and beta-glucans, which are currently used in leading skin care brands around the world. COSCIENS' lead pharmaceutical product Macimorelin (Macrilene; Grivelin) is the first and only U.S. Food and Drug Administration (“FDA”) and European Medicines Agency (“EMA”) approved oral test for the diagnosis of adult growth hormone deficiency (AGHD).
The Company's common shares are listed on the Toronto Stock Exchange (the “TSX”) under the symbol “CSCI.” As of September 4, 2025, FINRA's Market Operations Department assigned the company's common stock the trading symbol “CSCIF” for listing and trading on the unquoted securities market (i.e., the “over-the-counter market” or “over-the-counter” market) in the United States. For more information, visit the COSCIENS website at: www.cosciensbio.com.
Forward-Looking Statements
Certain statements in this press release referred to herein as “forward-looking statements” constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended, and “forward-looking information” within the meaning of Canadian securities laws. All statements, other than statements of historical fact, that address circumstances, events, actions or developments that may or may occur are forward-looking statements. When used in this MD&A, words such as “expect,” “anticipate,” “believe,” “may,” “anticipate,” “forecast,” “future,” “target,” “guidance,” “intend,” “likely,” “may,” “will,” or the negative or comparable terminology, as well as terms generally used in future and contingent, are generally intended to identify forward-looking statements, although not all forward-looking statements include such words. Forward-looking statements in this press release include, but are not limited to, statements regarding the expectations of the interim CEO.
These statements are based on current expectations and assumptions, including factors or assumptions, factors or assumptions that were applied in making the conclusion or forecast or forecast, including assumptions based on historical trends, current conditions and expected future events. Because forward-looking statements address future events and conditions, by their very nature they require assumptions and involve inherent risks and uncertainties. The Company cautions that while the assumptions are believed to be reasonable under the circumstances, these risks and uncertainties cause actual results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, the factors described under “Risks Related to Us and Our Business” in the Company’s Annual Report on Form 20-F for the year ended December 31, 2024. Given these risks, undue reliance should not be placed on them. Forward-looking statements speak only as of the date made. We disclaim any obligation to update any such risks or uncertainties or to publicly announce any changes to any forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by governmental authority or applicable law.
Issuer contact person:
Peter H. Puccetti
Interim CEO and Chairman of the Board
[email protected]
Giuliano La Fratta
Financial Director
[email protected]
Investor contact person:
[email protected]
